Pharmacology & Therapeutics
April 6, 2024
Zarah R. Haniff, Mariia Bocharova, Tim Mantingh et al.
16 citations
Major depression is an established risk factor for subsequent dementia, and depression in late life may also represent a prodromal state of dementia. Considering current challenges in the clinical development of disease modifying therapies for dementia, the focus of research is shifting towards prevention and modification of risk factors to alter the neurodegenerative disease trajectory....
Journal of Psychedelic Studies
April 5, 2024
Brian Pilecki, Jason B. Luoma, Kati M. Lear
9 citations
Abstract Psychological flexibility has been proposed as a core process of change when psychedelics are used for therapeutic purposes, but to date empirical outcomes have only documented changes on the Acceptance and Action Questionnaire (AAQ-II), a very general measure of psychological flexibility. This pilot study measured outcomes from psilocybin administered in a retreat setting across a...
April 2, 2024
Harman Chopra, Timothy Furnish, Monica Verduzco-Gutierrez et al.
IntroductionCoronavirus disease 2019 (COVID-19) is a highly contagious respiratory illness caused by the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). The virus was first identified in Wuhan, China in December 2019 and has since spread
Journal of Psychedelic Studies
April 2, 2024
M. Nordin, Jón Ingi Hlynsson, Jakob Håkansson Eklund et al.
17 citations
Abstract Background and aims Interest in psychedelic research has grown significantly in recent years and the naturally derived substance psilocybin, in combination with therapy, has shown promising results as a treatment for a range of psychiatric conditions. However, the negative effects and risks of psilocybin-assisted treatment are not well-established. The purpose of this study was to...
Trends in molecular medicine
April 1, 2024
Trevor Steward
The neurobiology of eating disorders [EDs; anorexia nervosa (AN), bulimia nervosa (BN), and binge eating disorder (BED)] remains poorly understood. Here, I describe how neuroimaging, accompanied by peripheral endocrine measures, can provide insights into the neurobiological drivers of eating disorders. Orexins/hypocretins, glucagon-like peptide-1 receptor (GLP1R) agonists, and psilocybin are...
European Psychiatry
April 1, 2024
Venessa Tsang, C. Roney
1 citation
Introduction Psilocybin-assisted therapy (PAT) has demonstrated significant potential in alleviating anxiety, depression, and psychological distress among individuals with terminal illnesses. However, numerous barriers prevent equitable access to this transformative treatment. Objectives This study seeks to gather the perspectives of patients on the waitlist of PAT. Methods Semi-structured...
Nervenheilkunde
April 1, 2024
Eva Maria Schindowski, Franz X. Vollenweider
ZUSAMMENFASSUNG Der Artikel stellt 2 Behandlungsverläufe von Patienten mit rezidivierender Depression gegenüber, welche mit Psilocybin behandelt wurden. Weltweit wächst stetig die Anzahl Studien, die die Verwendung von Psilocybin zur Behandlung von Depressionen untersuchen und damit mehr und mehr das Interesse an dieser Therapieform. Während einige Kollegen aus dem Forschungsumfeld einen...
Fortschritte der Neurologie · Psychiatrie
April 1, 2024
Psilocybin ist ein Indolalkaloid aus der Gruppe der Tryptamine und wird zur Behandlung behandlungsresistenter Depressionen (TRD) untersucht. Da die Einnahme von Antidepressiva die psychedelische Wirkung von Psilocybin potenziell verändern kann, werden diese vor Studienbeginn regelhaft ausgeschlichen. Goodwin et al. dagegen wollten prüfen, ob Psilocybin eine SSRI-Therapie bereichern kann, und...
Journal of Clinical and Translational Science
April 1, 2024
Broc A. Pagni, Petros Petridis, Samantha K. Podrebarac et al.
1 citation
OBJECTIVES/GOALS: This pilot study investigated psilocybin-induced changes in neural reactivity to alcohol and emotional cues in patients with alcohol use disorder (AUD). METHODS/STUDY POPULATION: Participants were recruited from a phase II, randomized, double-blind, placebo-controlled clinical trial investigating psilocybin-assisted therapy (PAT) for the treatment of AUD (NCT02061293). Eleven...
European Psychiatry
April 1, 2024
V. Tsang
Introduction While much is known about psilocybin-assisted therapy for individuals, little is known about the experience of participants in a group psilocybin therapy model. Objectives In an attempt to bridge this gap in the literature, a program development and quality improvement effort was launched. Methods Thirty-one psychedelic-assisted therapy (PaT) sessions were provided for 25...